Clinical Trial Update: Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection [VISION] [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial (VISION) is evaluating VIR-3434, an HBsAg monoclonal antibody, for chronic hepatitis B infection and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• VIR-3434

Snippet

Sponsor: University Health Network, Toronto | Conditions: Hepatitis B, Chronic | Phase 2 | Status: RECRUITING